-+ 0.00%
-+ 0.00%
-+ 0.00%

Solid Earnings May Not Tell The Whole Story For DongKoo Bio & Pharma (KOSDAQ:006620)

Simply Wall St·11/19/2026 23:00:02
Listen to the news

DongKoo Bio & Pharma Co., Ltd.'s (KOSDAQ:006620) robust recent earnings didn't do much to move the stock. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

earnings-and-revenue-history
KOSDAQ:A006620 Earnings and Revenue History November 19th 2026

The Impact Of Unusual Items On Profit

To properly understand DongKoo Bio & Pharma's profit results, we need to consider the ₩24b gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. We can see that DongKoo Bio & Pharma's positive unusual items were quite significant relative to its profit in the year to September 2026. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of DongKoo Bio & Pharma.

Our Take On DongKoo Bio & Pharma's Profit Performance

As previously mentioned, DongKoo Bio & Pharma's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that DongKoo Bio & Pharma's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing DongKoo Bio & Pharma at this point in time. While conducting our analysis, we found that DongKoo Bio & Pharma has 3 warning signs and it would be unwise to ignore these.

This note has only looked at a single factor that sheds light on the nature of DongKoo Bio & Pharma's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.